ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
11 Septiembre 2024 - 5:50AM
Business Wire
ANI and Alimera Scheduled the Closing for
September 16, 2024
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera
Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today
jointly announced that they have scheduled the closing of their
transaction pursuant to the companies’ previously announced Merger
Agreement for before the market opens on Monday, September 16,
2024.
About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc.
(Nasdaq: ANIP) is a diversified biopharmaceutical company serving
patients in need by developing, manufacturing, and marketing
high-quality branded and generic prescription pharmaceutical
products, including for diseases with high unmet medical need. ANI
is focused on delivering sustainable growth by scaling up its Rare
Disease business through its lead asset Purified Cortrophin® Gel,
strengthening its Generics business with enhanced research and
development capabilities, delivering innovation in Established
Brands, and leveraging its U.S. based manufacturing footprint.
About Alimera Sciences, Inc. Alimera Sciences is a global
pharmaceutical company whose mission is to be invaluable to
patients, physicians and partners concerned with retinal health and
maintaining better vision longer. For more information, please
visit www.alimerasciences.com.
Forward-Looking Statements This communication, and the
documents to which it refers you, contains not only historical
information, but also forward-looking statements made pursuant to
the safe-harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements represent the
parties’ expectations or beliefs concerning future events,
including the timing of the transaction and other information
relating to the transaction. Forward-looking statements include
information concerning possible or assumed future results of
operations of Alimera and/or ANI, the expected completion and
timing of the transaction and other information relating to the
transaction. Without limiting the foregoing, the words “believes,”
“anticipates,” “plans,” “expects,” “intends,” “forecasts,”
“should,” “estimates,” “contemplate,” “future,” “goal,”
“potential,” “predict,” “project,” “projection,” “may,” “will,”
“could,” “should,” “would,” “assuming” and similar expressions are
intended to identify forward-looking statements. You should read
statements that contain these words carefully. They discuss
Alimera’s and/or ANI’s future expectations or state other
forward-looking information and may involve known and unknown risks
over which the parties have no control. Those risks include, (i)
the risk that the transaction may not be completed at all, which
may adversely affect Alimera’s and/or ANI’s business and the price
of the common stock of Alimera and/or ANI, (ii) the outcome of the
legal proceedings related to the merger agreement or the
transaction, and (iii) risks related to diverting management’s
attention from Alimera’s and/or ANI’s ongoing business operations.
Forward-looking statements speak only as of the date of this
communication or the date of any document incorporated by reference
in this document. Further risks that could cause actual results to
differ materially from those matters expressed in or implied by
such forward-looking statements are described in the parties’
respective SEC reports. Except as required by applicable law or
regulation, neither party undertakes to update these
forward-looking statements to reflect future events or
circumstances.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910243285/en/
For ANI: Lisa M. Wilson, In-Site Communications, Inc. T:
212-452-2793 E: lwilson@insitecony.com For Alimera: Dan Zacchei /
Ashley Areopagita Longacre Square Partners E:
dzacchei@longacresquare.com / aareopagita@longacresquare.com
Alimera Sciences (NASDAQ:ALIM)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Alimera Sciences (NASDAQ:ALIM)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024